Introduction
============

In recent years, peptidoglycan‐degrading enzymes and bacteriophage endolysins in particular have received increasing attention as antimicrobial agents. In view of emerging and spreading resistance of pathogenic bacteria against classical antibiotics, there is an increasing demand for alternative antimicrobials. Especially in case of Gram‐positive bacteria, the application of phage endolysins is a promising approach ([@b34]; [@b37]; [@b12]; [@b31]; [@b32]; [@b3]; [@b20]; [@b13]). Due to the absence of an outer membrane in Gram‐positives, these enzymes also work when added from without, i.e. they can cause rapid lysis of susceptible cells. Numerous potential applications of lysins in food safety, agriculture, and medicine have been reported. Aiming towards the control of the opportunistic food‐borne pathogen *Listeria monocytogenes*, genes encoding *Listeria*‐specific phage endolysins were introduced into starter organisms used in cheese production; and secretion of the active enzymes from the bacteria provided them with lytic activity against *Listeria* ([@b14]; [@b45]). Other reports include the detection and killing of *Bacillus anthracis* ([@b43]), *Staphylococcus aureus* in milk ([@b38]; [@b17]) and MRSA *in vitro* ([@b1]), and the control of *Streptococcus pneumoniae* in different models ([@b30]; [@b37]; [@b22]; [@b29]; [@b6]).

Like all endolysins from a Gram‐positive background, *Listeria* phage endolysins show a modular organization in which catalytic activity and substrate recognition are separated: they consist of two functional domains, an N‐terminal enzymatically active domain (EAD) and a C‐terminal cell wall‐binding domain (CBD) ([@b34]; [@b36]). The EAD determines the enzymatic mechanism of the endolysin. The CBD of an endolysin binds to a certain ligand within the bacterial cell wall, thereby bringing the EAD in proximity to its substrate. In general, cell wall lytic enzymes can assume at least four different enzymatic activities ([@b49]; [@b31]). Among the *Listeria* phage endolysins, two classes exist: *N*‐acetylmuramoyl‐[l]{.smallcaps}‐alanine amidases cleave between the sugar and the peptide moieties, and the unique [l]{.smallcaps}‐alanoyl‐[d]{.smallcaps}‐glutamate peptidases target the bond between [l]{.smallcaps}‐alanine and [d]{.smallcaps}‐glutamate in the peptide chain ([@b34]).

The CBD confers high specificity and binding affinity to the endolysin. *Listeria* phage CBDs bind independent of species boundaries, but recognize certain carbohydrate components associated with the murein which also determine the serovar groups within the genus of *Listeria*; they show very little or no cross‐reactions with other bacteria ([@b36]; [@b42]). These attractive properties have been harnessed for development of specific diagnostics tools for *Listeria* ([@b36]); even multiplex differentiation of strains by fluorescent reporter--CBD fusion proteins is possible ([@b42]). In addition, *Listeria* phage CBDs have been used for affinity‐based magnetic separation (CBD‐MS) of target cells from food matrices, and this method was demonstrated to be superior to standard detection protocols ([@b28]; [@b42]; [@b46]).

Until now, the PlyPSA amidase from *L. monocytogenes* phage PSA ([@b50]) and the Ply500 peptidase domain from phage A500 ([@b34]) are the only *Listeria* endolysins for which structural data exist ([@b26; @b27]). The PlyPSA crystal structure revealed two distinct domains connected by a short, but highly flexible linker region ([@b26]). Sequence alignments showed the presence of similar linkers in other *Listeria* phage endolysins, and revealed strong sequence homologies among the enzymes ([@b36]; [@b42]). This may include entire domains, such as in PlyPSA, whose CBD is highly similar to that of Ply500, whereas the EADs are unrelated. The EAD of Ply500, however, is nearly identical to that of Ply006 ([@b42]). This suggests frequent exchange of these functional modules by horizontal gene transfer, enabling a highly variable mix‐and‐match of domain combinations within the phage population. It was therefore reasonable to assume that this variability could be further extended by artificial recombination of functional domains, thereby creating chimeric proteins with desired properties. In this study, we have created chimeric proteins by defined fusions of EADs and CBDs from various *Listeria* phage endolysins, using GFP as a fluorescent reporter. We were able to modulate lytic properties of endolysins by exchange of EADs and CBDs, to extend the binding range of reporter--CBD fusion proteins by combination of CBDs with different specificities, and created proteins with duplicated CBDs, which represents a novel and unique strategy to significantly increase binding affinity to bacterial cell surfaces.

Results
=======

Combination of EADs and CBDs of different origin generates proteins with swapped specificity and enhanced lytic activity
------------------------------------------------------------------------------------------------------------------------

The *N*‐acetylmuramoyl‐[l]{.smallcaps}‐alanine amidase PlyPSA features a CBD specifically targeting cell walls of *Listeria* strains belonging to serovars 4, 5 or 6 ([@b26]). In contrast, the CBD of the [l]{.smallcaps}‐alanoyl‐[d]{.smallcaps}‐glutamate peptidase Ply118 ([@b34]) only recognizes strains of serovars 1/2, 3 and '7' ([@b36]; see *Discussion* below). Based on the crystal structure of PlyPSA ([@b26]) and the *in silico* identified putative linker region between EAD and CBD of Ply118 ([@b42]), a series of fusion proteins was created featuring CBDPSA including its linker fused to the C‐termini of putative EAD118 fragments in three different length variants. In a complementary approach, the EAD of PlyPSA including the linker was fused to the N‐termini of six different CBD118 fragments ([Fig. 1A](#f1){ref-type="fig"}). The four longer variants (CBD118 D, C, B, A1), which include the putative linker region of Ply118 and portions of different length of the C‐terminal end of the EAD118, had been shown to be sufficient for directing the green fluorescent protein in GFP--CBD fusion proteins to the cell surface of susceptible strains ([@b36]). The two shorter variants, A2 and A3, only comprise the CBD and parts of the putative linker.

![Lytic activities of native endolysins and engineered fusion proteins against *Listeria* cells. Schematic representations of the different constructs tested here are shown in (A). The table in (B) lists relative lytic activities (mean values and standard deviations) determined from lysis curves as shown for serovar 1/2c strain WSLC 1001 (C) and serovar 4b strain WSLC 1042 (D). PlyPSA and Ply118 served as references. The changes in optical density over a period of 300 s after addition of EAD118_I\_CBDPSA (□), EAD118_II_CBDPSA (◊), EAD118_III_CBDPSA (Δ), PlyPSA (![](mbt0004-0651-fu1.jpg)) and Ply118 (●) to cell suspensions are shown. Buffer was added as control (x). Curves were normalized and recalculated to an initial OD at 600 nm of 1.0.](mbt0004-0651-f1){#f1}

Following overexpression and purification, lytic activities of all chimeric enzymes were determined by photometric lysis assays using *L. monocytogenes* WSLC 1001 (serovar 1/2c) and WSLC 1042 (serovar 4b) cells in suspension. The parental endolysins Ply118 ([@b35]) and PlyPSA ([@b26]) ([Fig. 1B](#f1){ref-type="fig"}) were used as controls. As expected with respect to the specificity of CBDPSA for WSLC 1042, the full‐length endolysin PlyPSA exhibited strong lytic activity against this strain, whereas it was not able to lyse WSLC 1001. Surprisingly, Ply118 did not only work against WSLC 1001 which its CBD recognizes, but was also able to very efficiently lyse cells of WSLC 1042 (142.4% activity compared with PlyPSA; please see *Discussion*).

The lysis of cells of both serovar groups by the chimeras containing EAD118 and CBDPSA as well as those of the native endolysins are shown in [Fig. 1C and D](#f1){ref-type="fig"}. None of the EAD118_CBDPSA fusions was able to lyse strain WSLC 1001, while all of them displayed strong activity against WSLC 1042. For all three length variants, lytic activity against the serovar 4b strain was considerably higher than that of both parental endolysins (up to threefold compared with the reference protein PlyPSA) ([Fig. 1B](#f1){ref-type="fig"}). These results demonstrate that functional chimeric proteins with swapped lytic specificities can be generated by exchange of the CBD of a *Listeria* phage endolysin. By replacing the native CBD in Ply118 by that of PlyPSA, the lytic activity of this enzyme against the serovar 1/2 strain was abolished, whereas that against the serovar 4 strain was enhanced.

All EADPSA_CBD118 fusion proteins constructed in this work exhibited lytic activity against both WSLC 1001 and WSLC 1042, which was, however, generally lower than the activities of the parental endolysins ([Fig. 1B](#f1){ref-type="fig"}). The exchange of the native CBD of PlyPSA, which is not able to lyse WSLC 1001, by that of Ply118 rendered the enzyme active against the serovar 1/2 strain. Activity against the serovar 4b strain was not completely abolished, but considerably reduced by this substitution. The effect of different length variants of single modules on the lytic activity of similar fusion proteins is apparent, especially among the different EADPSA_CBD118 constructs. The EADPSA_CBD118_A2 enzyme displayed the highest lytic activity, with 41.7% compared with PlyPSA against WSLC 1042 and 62.3% compared with Ply118 against WSLC 1001.

Combination of CBDs of different specificity extends binding range
------------------------------------------------------------------

Fusion proteins consisting of an N‐terminal GFP domain and a C‐terminal CBD from any *Listeria* phage endolysin can be used to fluorescently decorate bacterial cell walls, which enables rapid qualitative determination of CBD association to various bacteria ([@b36]; [@b42]). Based on the complementary specificities of CBD118 and CBD500 ([@b36]), we aimed to create fusion proteins with an extended binding range by combination of both CBDs in one heterodimer. CBD500 exhibits binding properties highly similar to those of CBDPSA; it evenly decorates the entire surface of *Listeria* cells of serovars 4, 5 and 6, but features stronger affinity and higher binding density than the CBDPSA ([@b42]). CBD118 is specific for serovar 1/2 and 3 cells ([@b36]), where it primarily targets polar and septal regions of the rod‐shaped murein sacculus.

Schematic representations of double CBD constructs created in this work are shown in [Fig. 2](#f2){ref-type="fig"}. The results of binding assays using a large set of *Listeria* strains comprising the six major species and all serovars with all constructs described here and single CBDs as reference are summarized in [Table 1](#t1){ref-type="table"}. The GFP_CBD500‐118 and GFP_CBD118‐500 proteins, in which both CBDs are directly fused to each other in both orientations and are tagged by an N‐terminal GFP, revealed binding to serovar 4, 5 and 6 cells, albeit with a somewhat weaker intensity. This demonstrated proper function of CBD500 in both N‐terminal and C‐terminal position. However, because this corresponded to the binding pattern of CBD500 only, it also indicated that CBD118 is non‐functional in these conformations.

![Schematic representations of all GFP and CBD fusions created and tested in this work, as well as the reference constructs GFP_CBD500 and GFP_CBD118 ([@b36]). GFP = green fluorescent protein; CBD500, CBD118, CBDP35 = cell wall‐binding domains of *Listeria* phage endolysins Ply500, Ply118 and PlyP35 respectively; L = linker region of PlyPSA.](mbt0004-0651-f2){#f2}

###### 

Binding of various GFP‐tagged CBD constructs from *Listeria* phage endolysins to *Listeria* cells from different species and serovars.

  Species                               Strain (WSLC)                         Source        SV     Binding of GFP_CBD\_                                                     
  ------------------------------------- ------------------------------------- ------------- ------ ---------------------- ----- ----- ---- ---- ---- ----- ----- ---- ----- -----
  *L. monocytogenes*                    EGDe                                  J. Kreft      1/2a   −                      ++    ++    −    −    \+   (+)   (+)   −    ++    ++
  *L. monocytogenes*                    10403S                                D. Portnoy    1/2a   −                      ++    ++    −    −    −    −     (+)   −    ++    \+
  *L. monocytogenes*                    1442[c](#t1n3){ref-type="table-fn"}   Food          1/2a   −                      ++    −     −    −    \+   \+    (+)   \+   −     −
  *L. monocytogenes*                    1066                                  SLCC 8800     1/2b   −                      ++    ++    −    −    −    −     (+)   −    ++    ++
  *L. monocytogenes*                    1001                                  ATCC 19112    1/2c   −                      ++    ++    −    −    −    −     (+)   −    ++    ++
  *L. seeligeri*                        4007                                  ATCC 35967    1/2b   −                      ++    ++    −    −    \+   \+    (+)   −    ++    ++
  *L. welshimeri*                       50149                                 SLCC 5877     1/2b   −                      ++    \+    −    −    \+   \+    (+)   −    (+)   (+)
  *L. monocytogenes*                    1485                                  Soft cheese   3a     −                      \+    \+    −    −    −    −     −     −    ++    ++
  *L. monocytogenes*                    1031                                  SLCC1694      3b     −                      \+    ++    −    −    −    −     −     −    ++    ++
  *L. monocytogenes*                    1032                                  SLCC 2479     3c     −                      \+    ++    −    −    −    −     −     −    ++    ++
  *L. seeligeri*                        40127                                 SLCC 8604     3b     −                      \+    ++    −    −    −    −     −     −    ++    ++
  *L. monocytogenes*                    1034[c](#t1n3){ref-type="table-fn"}   SLCC 2482     '7'    −                      \+    −     −    −    −    −     −     −    −     −
  *L. monocytogenes*                    1020                                  ATCC 19114    4a     ++                     −     ++    \+   \+   \+   ++    \+    ++   ++    ++
  *L. monocytogenes*                    1042                                  ATCC 23074    4b     ++                     −     −     \+   \+   \+   ++    \+    ++   ++    ++
  *L. monocytogenes*                    ScottA                                J. Jay        4b     ++                     −     −     \+   \+   \+   ++    \+    ++   ++    ++
  *L. monocytogenes*                    1019                                  ATCC 19116    4c     ++                     −     ++    \+   \+   \+   ++    \+    ++   ++    ++
  *L. monocytogenes*                    1033                                  ATCC 19117    4d     ++                     −     \+    \+   \+   \+   ++    \+    ++   ++    ++
  *L. monocytogenes*                    1018                                  ATCC 19118    4e     ++                     −     (+)   \+   \+   \+   ++    \+    ++   ++    ++
  *L. ivanovii*                         3009                                  SLCC 4769     5      ++                     −     ++    \+   \+   \+   ++    \+    ++   ++    ++
  *L. ivanovii* (ssp. *ivanovii*)       3010                                  ATCC 19119    5      ++                     −     ++    \+   \+   \+   ++    \+    ++   ++    ++
  *L. ivanovii* (ssp. *londoniensis*)   3060                                  SLCC 3765     5      ++                     −     −     \+   \+   \+   \+    (+)   \+   \+    \+
  *L. innocua*                          2011                                  ATCC 33090    6a     ++                     −     −     \+   \+   \+   \+    (+)   \+   ++    ++
  *L. innocua*                          2012                                  ATCC 33091    6b     ++                     −     ++    \+   \+   \+   ++    \+    ++   ++    ++
  *L. welshimeri*                       50146                                 SLCC 7622     6a     ++                     −     \+    \+   \+   \+   ++    \+    ++   ++    ++
  *L. grayi* (ssp. *grayi*)             6036                                  ATCC 19120    −      (+)                    (+)   ++    −    −    −    −     −     −    \+    ++
  *L. grayi* (ssp. *murrayi*)           6037                                  ATCC 25401    −      (+)                    (+)   ++    −    −    −    −     −     −    ++    ++

[@b36]).

[@b42]).

Strains 1442 and 1034 are mutants and lack *N*‐acetyl glucosamine in their wall teichoic acids.

++, strong; +, weak; (+), very weak; −, no binding.

Assuming that enhanced flexibility of both binding domains in a fusion construct might render CBD118 functional, GFP_CBD500L118 and GFP_CBD118L500 were created, which employ the linker peptide of PlyPSA ([@b26]) for separating the CBDs. Again, both constructs nicely decorated serovar 4, 5 and 6 cells, similar to single GFP_CBD500 ([Fig. 3D--F](#f3){ref-type="fig"}). Moreover, it also labelled four out of seven of the serovar 1/2 strains tested. The latter were predominantly marked at the poles and septa ([Fig. 3B and C](#f3){ref-type="fig"}), as observed for single GFP_CBD118 ([Fig. 3A](#f3){ref-type="fig"}) ([@b36]). Obviously, these heterologous dual CBD fusions combined the recognition and binding properties from both CBDs, even though binding among the serovars 1/2 and 3 strains seems to be more selective than that of GFP_CBD118 alone. The dimeric CBD fusion GFP_CBD118L500 displayed binding to serovar 4, 5 and 6 strains almost indistinguishable from monomeric GFP_CBD500. In conclusion, introduction of the native linker peptide from PlyPSA not only enabled CBD118 to better access its ligands, but it also permitted full functionality of CBD500 in the C‐terminal location.

![Decoration of *Listeria monocytogenes* cells by fluorescently tagged phage endolysin CBDs. *Listeria* cells of strains WSLC 1442 (A--C) and WSLC 1042 (D--F) were labelled using GFP_CBD118 (A) and GFP_CBD500 (D) (controls), and dual CBD fusions GFP_CBD500L118 (B, E) and GFP_CBD118L500 (C, F). Images were taken using epifluorescent microscopy.](mbt0004-0651-f3){#f3}

We also created fusions featuring GFP in a central position acting as a spacer, with CBD500 and CBD118 located at the N‐ or C‐termini. In CBD500_GFP_CBD118, where CBD118 is located similarly to the situation in the native enzyme or in monomeric GFP_CBD118, it recognized all serovar 1/2 strains, even though the decoration was weak. In CBD118_GFP_CBD500, the orientation of the CBDs is reversed, and only weak labelling of one serovar 1/2 strain was observed. As a conclusion, CBD118 function is highly dependent on domain location, while CBD500 functionality seemed to be less influenced by these constraints.

To further optimize recognition of and binding to *Listeria* serovar 1/2 cells by recombineered CBDs, CBD118 was replaced by CBDP35 in another series of heterodimeric dual CBD proteins. The CBDP35 polypeptide had recently been shown to strongly bind to strains of serovars 1/2, 3, and even some strains of serovars 4, 5 and 6, in a CBD500‐like fashion, i.e. over the entire cell surface ([@b42]) (see [Table 1](#t1){ref-type="table"}). In fact, labelling of cells by recombinant GFP_CBD500‐P35 and GFP_CBDP35‐500 nicely combined the properties of the single CBD500 and CBDP35. Both constructs showed strong binding to all strains which are recognized by CBD500 or by CBDP35 or both. This was regardless of the spatial location of the single CBDs within the fusions, indicating that both CBDs are fully functional within the chimeric proteins.

Tandem duplication of CBD500 strongly increases binding affinity
----------------------------------------------------------------

We questioned whether the duplication of a CBD would result in higher binding affinity to the cell wall, and constructed GFP_CBD500‐500, which features tandem CBD500 domains fused to an N‐terminal GFP ([Fig. 4A](#f4){ref-type="fig"}). Kinetic data of the interaction of both GFP_CBD500 and GFP_CBD500‐500 with the cell wall of *L. monocytogenes* WSLC 1042 cells were obtained by surface plasmon resonance (SPR) analysis. Real‐time kinetic data were measured by applying GFP_CBD500 or GFP_CBD500‐500 onto immobilized bacterial cells. The equilibrium association constants obtained for three different concentrations of each protein reflect the affinities to the cell wall ([Table 2](#t2){ref-type="table"}). GFP_CBD500‐500 was shown to bind to the *Listeria* cells with approximately 50‐fold higher affinity compared with GFP_CBD500, with equilibrium constants in the pico‐molar range. When overlaying sensorgrams of both the single and the double CBD protein ([Fig. 4B](#f4){ref-type="fig"}), it became obvious that the proteins mainly differ in the dissociation phase. In other words: when bound to the cell surface, GFP_CBD500 detaches easier than GFP_CBD500‐500, resulting in the higher overall affinity of the double CBD construct.

![Effect of CBD500 duplication on binding properties and lytic activity. A. Schematic representation of tandem CBD500 fusion proteins and the single CBD500 reference proteins. GFP = green fluorescent protein; EAD500 = enzymatically active domain ([l]{.smallcaps}‐alanoyl‐[d]{.smallcaps}‐glutamate peptidase) of *Listeria* phage endolysin Ply500; CBD500 = cell wall‐binding domain of Ply500. B. Overlay of SPR sensorgrams showing association and dissociation phases of GFP_CBD500 and GFP_CBD500‐500, respectively, to the cell walls of *L. monocytogenes* WSLC 1042, measured at a protein concentration of 50 nM. RU = relative response units. C. Relative lytic activity of Ply500 (○) and EAD_CBD500‐500 (![](mbt0004-0651-fu2.jpg)) on WSLC 1042 cells at different NaCl concentrations. All assays were carried out in triplicate.](mbt0004-0651-f4){#f4}

###### 

Equilibrium affinity constants (*K*~A~) of GFP_CBD500 and GFP_CBD500‐500 binding to the cell wall of *Listeria monocytogenes* serovar 4b strain WSLC 1042.

  GFP_CBD500   GFP_CBD500‐500          
  ------------ ---------------- ------ ---------------
  200          5.61 × 10^8^     50     1.00 × 10^10^
  100          6.50 × 10^8^     25     5.61 × 10^10^
  50           5.96 × 10^8^     12.5   2.19 × 10^10^
  Mean         6.02 × 10^8^     Mean   2.93 × 10^10^

Final values are arithmetic means calculated from three different analyte concentrations tested.

Increased affinity improves endolysin activity at high ionic strength
---------------------------------------------------------------------

It was suggested that ionic interaction by way of charge plays a major role as the molecular basis for association of CBDs to their cell wall ligands. Monomeric CBD500 shows optimum binding at 100--150 mM NaCl, which decreases with increasing salt concentration, i.e. ionic strength ([@b36]). Therefore, we reasoned that an endolysin featuring two identical binding domains such as a duplicated CBD500 should exhibit stronger activity than native Ply500 at high salt concentrations, due to higher affinity of the double CBD domain. In order to test this, EAD_CBD500‐500 (see [Fig. 4A](#f4){ref-type="fig"}) was made and its lytic activity determined against *L. monocytogenes* WSLC 1042 cells at different salt concentrations. As shown in [Fig. 4C](#f4){ref-type="fig"}, lytic activity of the tandem CBD construct was approximately sixfold lower than that of Ply500 at the standard NaCl concentration. However, with increasing ionic strength, the differences in activity between both enzymes became smaller and both curves intersected between 500 and 1000 mM. At even higher NaCl concentrations, EAD_CBD500‐500 exhibited higher lytic activity than Ply500 (approximately twofold at 1500 M), demonstrating that the enhanced affinity also supports binding and thereby enzyme activity at higher ionic strength.

Discussion
==========

The available data suggest that many proteins encoded by bacteriophage genomes such as murein hydrolases share a common ancestry with related enzymes from the bacterial hosts, and have co‐evolved by recombination‐driven interchange of functional domains ([@b18]; [@b20]). This characteristic modular organization, in which the specific functions of substrate recognition and catalysis are physically separated and independent, appears beneficial for enzymes degrading polymeric insoluble substrates such as peptidoglycan ([@b47]; [@b7]). These domains represent stable globular polypeptides that can fold autonomously ([@b39]), and can be recombined to create novel functions ([@b25]). Strong evidence for a modular mix‐and‐match in *Listeria* phages endolysins was provided by a recent comprehensive study on these endolysins ([@b42]).

We here demonstrate that the natural variability found within the *Listeria* endolysins can be further extended by artificial design and recombination of functional modules, generating novel proteins with optimized properties. Fusions of EADs and CBDs from endolysins PlyPSA and Ply118 provided proof of concept for interchangeability of domains within these enzymes. Switching the CBDs of two endolysins resulted in a swap of their binding and lysis specificity. Similar observations have been reported for autolysins from *Streptococcus* and *Clostridium*, and pneumococcal and lactococcal phage endolysins ([@b9]; [@b7],[@b8]; [@b44]). Recently, Becker and co‐workers reported that streptococcal lysins became active against *S. aureus* cells following exchange of their CBDs against *Staphylococcus*‐specific binding modules ([@b2]).

With respect to cell lysis in suspension, Ply118 was found to efficiently lyse cells of WLSC 1042, whereas its isolated CBD118 alone does not recognize and bind to these cells ([@b36]). This suggest that in suspension of cells and lytic enzyme, where the enzyme is added at a large excess, the CBD is not required for lytic activity and presence of a high enough concentration of EAD may be sufficient to cause lysis from without. In its natural context, i.e. when the endolysin is produced inside the bacterial host cell at the end of the phage multiplication cycle, enzyme concentration is much lower, and high‐affinity targeting might be necessary to achieve timely and efficient cell lysis. Moreover, after disruption of the host cell it is important that the liberated endolysins remain attached to cell wall debris of the host, thereby preventing collateral damage to neighbouring host cells which have not yet produced phage ([@b36]). Cell lysis by an 'isolated' catalytic domain has also been reported for LytC, an autolysin of *S. pneumoniae* ([@b16]), as well as PlyPSA, whose EAD could still lyse *Listeria* cells, albeit activity was reduced to only 15% ([@b26]). The extent of such non‐specific lysis presumably depends on the susceptibility of the cells and the nature of the EAD. In this context, it was interesting to note that EAD118_CBDPSA, which combines lytic activity of EAD118 (serovar 1/2 background) with specificity of CBDPSA (serovar 4 background), was found to have higher activity on serovar 4 strains than any of the parental endolysins. However, in contrast to the serovar 4 strain WSLC 1042, the serovar 1/2 strain WSLC 1001 was only lysed by enzymes containing a corresponding CBD118 module, which indicates that this cell wall type requires a certain binding affinity of the enzyme.

CBD500 retained its functionality and binding properties regardless of its N‐ or C‐terminal location within a heterologous construct. The majority of bacteriophage endolysins and bacterial peptidoglycan hydrolases from Gram‐positive organisms feature at least one catalytic domain at the N‐terminus, and a CBD at the C‐terminus. However, inverse orientations have also been reported ([@b16]). On the other hand, the various constructs made during the course of this work also disclose some limitations of 'artificial' domain engineering. CBD118 never exhibited full functionality as in native Ply118 or GFP_CBD118 in any of the chimaeras; modifications resulted in either a narrower binding range, weaker binding or complete loss of function. The most likely explanation is improper overall conformation of the recombinant constructs, whose folding and stability depend on domain interactions and the nature of linker regions which influences the orientation of the proteins relative to their ligands in the cell wall. Accessibility of the ligands recognized by CBD118 might play a role, and this could be limited by sterical considerations. This possibility is supported by our findings that inclusion of a suitable linker to provide more flexibility between the domains also enhanced the recognition function of CBD118. We previously showed that CBDs from *Listeria* phage endolysins fused to fluorescent proteins can serve as tools for specific detection of *Listeria* cells, making it possible to even simultaneously detect and distinguish different strains ([@b36]; [@b42]), and can be used for efficient immobilization and capture of bacteria when coated onto paramagnetic beads ([@b28]). The findings presented here demonstrate that modular engineering of CBDs can provide a tailor‐made toolbox ideally suited for such purposes requiring high specificity and high‐affinity proteins. Both CBD500 and CBDP35 exhibit affinity constants in the nanomolar range and show little cross‐reactions with other bacteria than *Listeria* ([@b36]; [@b42]). Since the GFP_CBD500‐P35 and GFP_CBDP35‐500 fusions combine the binding ranges of both CBDs, they represent ideal reagents for CBD‐based magnetic separation assays (CBD‐MS) ([@b28]). They recognize the vast majority of all *Listeria* strains, except for those few strains (WSLC 1442, WSLC 1034) lacking the N‐acetylglucosamine substitution at the C4 position of their poly‐ribitol phosphate teichoic acids, which are specifically recognized and bound by CPBP35. However, these strains are extremely rare, and actually feature mutations in the serovar 1/2‐type teichoic acid glycosylation pathway (M. Eugster and M.J. Loessner, submitted).

Several murein hydrolases feature specific motifs or repeats in their cell wall‐recognizing domains ([@b15; @b16]; [@b24]), and it was suggested that the number of such motifs and repeats may determine the binding affinity ([@b48]). Our data regarding the tandem repeat in CBD500‐500 demonstrate that this is also applicable to the domain level, as the duplication of CBD500 resulted in a drastic increase in equilibrium affinity, brought about by lowering the dissociation rate (*k*~d~), whereas the association (*k*~a~) was similar to that of the monomeric polypeptide ([@b36]) ([Fig. 4B](#f4){ref-type="fig"}). An elegant explanation is that the detachment of the single CBD in GFP_CBD500 would always result in displacement of the protein. In contrast, if one of the two CBDs of GFP_CBD500‐500 detaches, the protein remains bound with the second CBD, providing it with ample time to re‐attach to its ligand.

Presence of a CBD is required for maximum lytic activity of a murein hydrolase ([@b41]; [@b26]). By attaching to a ligand in the cell wall, the local enzyme concentration is elevated and the EAD is positioned in proximity to its substrate. Other authors reported that absence or presence of a putative CBD may not influence lytic activity ([@b5]). We found that duplication of CBD in Ply500, which increases binding affinity of the protein, reduces lytic activity against intact cells in suspension, suggesting that stronger binding does not necessarily correlate with increasing cell lysis. Apparently, a lytic enzyme should retain a certain degree of surface mobility for optimal lytic activity, as suggested for Cpl‐1 and modular bacterial cellulases ([@b23]; [@b19]). However, under specific environmental conditions, stronger binding may also support lysis, as shown by the fact that at elevated ionic strength, EAD_CBD500‐500 works better than the non‐modified enzyme. Thus, engineered enzymes could be useful for lysis of target bacteria in specific environments such as foods with elevated salt content, e.g. cheese surfaces, cured fish and meat products.

Our work shows that modular engineering of bacteriophage endolysins is helpful to provide specifically tailored, optimized tools for the detection and lysis of bacterial pathogens. A recent report of an endolysin fused to a membrane‐disrupting peptide demonstrated that Gram‐negative organisms can also be targeted by these enzymes ([@b4]). Considering that the *Caudovirales* represent the most abundant self‐replicating units on earth, the toolbox of enzymatically active and cell wall‐binding modules seems virtually unlimited.

Experimental procedures
=======================

Bacteria, culture conditions, plasmids and phages
-------------------------------------------------

*Escherichia coli* XL1‐Blue MRF\' (Stratagene) served for cloning and overexpression of 6xHis‐tagged phage endolysins and the various constructs made throughout this work, and it was cultured in LB (Luria--Bertani) medium at 30°C with 100 µg ml^−1^ ampicillin and 30 µg ml^−1^ tetracycline for plasmid selection. Photometric lysis assays of cells in suspension were performed with *L. monocytogenes* WSLC 1001 (serovar 1/2c) and WSLC 1042 (serovar 4b). Twenty‐six *Listeria* strains comprising the six major species and all serovars ([Table 1](#t1){ref-type="table"}) were used for the CBD binding assays. *Listeria* were cultured in TB (tryptose broth) medium at 30°C.

The plasmids pHPLPSA ([@b26]), pHPL118 and pHPL500 ([@b35]), and genomic DNA of phage P35 ([@b11]) were used as templates for amplification of EAD and/or CBD coding regions of endolysins PlyPSA, Ply118, Ply500 and PlyP35 respectively. The plasmid pHGFP ([@b36]) served as template for the amplification of the *gfp*‐coding sequence. Plasmid pQE‐30 (Qiagen) and its derivatives pHGFP, pHGFP_CBD118, pHGFP_CBD500 ([@b36]), and pHEADPSA ([@b26]), were used as backbones for the construction of vectors encoding N‐terminally 6xHis‐tagged fusion proteins (see Table S2).

DNA techniques and cloning procedures
-------------------------------------

Standard DNA manipulation and cloning procedures ([@b40]) were used for construction of plasmids encoding endolysin‐based fusion proteins. Enzymes were purchased from New England Biolabs, MBI Fermentas, Qiagen and Roche, and used according to manufacturer instructions. DNA fragments coding for functional domains of *Listeria* phage endolysins, as well as the GFP‐coding fragment were amplified from templates and with primers listed in Table S1 (*Supporting information*), using Proof Start DNA Polymerase (Qiagen) or High Fidelity PCR Enzyme Mix (MBI Fermentas). Restriction sites needed for insertion of the fragments into the plasmids were introduced via primer design. Concentrations of DNA fragments and plasmids were determined spectrophotometrically (NanoDrop ND‐1000).

All plasmids used and created in this work are listed in Table S2 (*Supporting information*). Plasmid pHCBDPSA was constructed by inserting a DNA fragment coding for the CBD of PlyPSA, including the flexible linker region between EAD and CBD, into SacI/SalI sites of pQE‐30. The position of the linker was derived from the resolved crystal structure of PlyPSA ([@b26]). In order to create a series of EAD118--CBDPSA chimeric proteins, three EAD118‐coding fragments of different length were cloned into BamHI/SacI sites of pHCBDPSA, upstream of the CBDPSA fragment, creating genetic fusions. In analogy, five different CBD118 fragments were inserted into SacI/SalI sites of pHEADPSA ([@b26]), yielding a series of EADPSA‐CBD118 constructs. Similar strategies were employed for creation of GFP‐double CBD constructs. CBD118 and CBD500‐coding fragments were joined via compatible EcoRI/MunI sites in both orientations, and then inserted into SacI/SalI sites of pHGFP, yielding pHGFP_CBD118‐500 and pHGFP_CBD500‐118. The plasmids pHGFP_CBDP35‐500 and pHGFP_CBD500‐P35 were created the same way. In case of pHGFP_CBD118L500 and pHGFP_CBD500L118, the fragment coding for the PlyPSA linker was introduced between the two CBDs by PCR‐based Gene Splicing by Overlap Extension PCR (SOE PCR) ([@b21]) before insertion into pHGFP. As for pHCBD500_GFP_118 and pHCBD118_GFP_500, the 5′ CBD and the GFP fragments were first joined via KpnI sites or by SOE PCR, and then ligated into BamHI/SacI sites of pHGFP_CBD118 and pHGFP_CBD500, respectively, replacing the *gfp* sequence in these plasmids. For construction of pHGFP_CBD500‐500, the CBD500 fragment was cloned into the SacI site of pHGFP_CBD500, resulting in a duplication of CBD500. pHEAD_CBD500‐500 was created by inserting the complete *ply*500 gene into BamHI/SacI sites of pHGFP_CBD500, replacing *gfp*.

The translational stop TAA was generally introduced as stop codon at the 3′ ends of the artificial coding sequences. All constructs were verified by nucleotide sequencing.

Synthesis and purification of His‐tagged protein constructs
-----------------------------------------------------------

Overproduction of His‐tagged fusion proteins in *E. coli* XL1‐Blue MRF\' was carried out as described before ([@b36]). The respective strains were grown in modified LB medium (15 g l^−1^ tryptose, 8 g l^−1^ yeast extract, 5 g l^−1^ NaCl) containing 100 µg ml^−1^ ampicillin and 30 µg ml^−1^ tetracycline for plasmid selection at 30°C, with 1 mM IPTG added as inducer once an OD~600~ of 0.4 was reached. After further incubation at 30°C for 4 h, cultures producing proteins that contain a GFP domain were further stored overnight at 4°C before harvesting and resuspension in 5 ml of buffer A (500 mM NaCl, 50 mM Na~2~HPO~4~, 5 mM imidazole, 0.1% Tween 20, pH 8.0) per 250 ml of culture. If no GFP was present, cultures were centrifuged 4 h after induction. Bacterial cells were disrupted by two passages through a French Press cell (SLM Aminco) at 100 MPa, cell debris removed by centrifugation (10 000 *g*, 10 min) and the supernatants filter‐sterilized (0.2 µM PES membrane, Millipore).

Then, His‐tagged proteins in the extracts were purified by immobilized metal affinity chromatography (IMAC) with Ni‐NTA Superflow resin (Qiagen) using Micro Biospin columns (Bio‐Rad). Buffer B (500 mM NaCl, 50 mM Na~2~HPO~4~, 250 mM imidazole, 0.1% Tween 20, pH 8.0) served as elution buffer. Eluates were dialysed against two changes of Dialysis Buffer (100 mM NaCl, 50 mM NaH~2~PO~4~, 0.005--0.1% Tween 20, pH 8.0), again filtered (0.2 µM PES membrane, Millipore), and stored at −20°C after addition of 50% (v/v) of glycerol. For each protein, intracellular synthesis and purification were monitored by SDS‐PAGE, and protein concentrations were determined spectrophotometrically (NanoDrop ND‐1000).

Photometric lysis assays
------------------------

The lytic activity of native His‐tagged endolysins and chimeric lytic proteins was determined by a photometric lysis assay as described before ([@b33; @b35]). Substrate cells of *L. monocytogenes* strains WSLC 1001 and WSLC 1042 were prepared by growing the bacteria in TB medium until late log phase, harvesting by centrifugation, resuspension in PBS (50 mM NaH~2~PO~4~, 120 mM NaCl, pH 8.0) at 50‐fold concentration and freezing at −80°C. Lysis assays were performed in a total volume of 1 ml, with cells diluted in PBS to an initial OD~600~ of approximately 1.0. All tested endolysins and chimeric enzymes were added to the cells in equimolar amounts (ranging from 30 to 152 pmol ml^−1^), and OD~600~ was measured at intervals of 15 s for total of 10 min. As negative control, PBS buffer was added to the cells. All assays were carried out in triplicate.

To examine the effect of NaCl concentration on lytic activity of Ply500 and EAD_CBD500‐500, assays were performed as described above, with final NaCl concentrations ranging from 100 mM to 2 M.

Data processing was carried out as described before ([@b26]). Lysis curves were normalized and corrected by subtraction of the controls \[corrected value = value + (1 − control value)\]. The resulting curves were fitted using the sigmoid function *f* = *y*0 + *a*/{1 + exp\[−(*x* − *x*0)/*b*\]}^∧^*c*, employing SigmaPlot 9.0 (Systat Software). The steepest slope of the function was used to calculate the relative lytic activity.

Cell wall binding assays and fluorescence microscopy
----------------------------------------------------

The binding properties of GFP--CBD fusion proteins were examined by binding assays as described before ([@b36]; [@b42]). In brief, late‐log‐phase cells in PBST buffer (50 mM NaH~2~PO~4~, 120 mM NaCl, pH 8.0, 0.01% Tween 20) were incubated with 10--20 ng of the GFP--CBD proteins for 5 min at room temperature. After washing twice with buffer, the cells were prepared for fluorescence microscopy, using an Axioplan microscope and an appropriate filter set (Carl Zeiss AG). Images of the fluorescently labelled cells were obtained by using a Leica DFC320 camera, and processed using appropriate software (Adobe Photoshop).

Determination of affinities by SPR analysis
-------------------------------------------

Affinities of GFP_CBD500 and GFP_CBD500‐500 to the cell wall of *L. monocytogenes* WSLC 1042 were determined by SPR analysis, using a BIAcore X instrument and the flat surface C1 sensor chips (BIAcore, Uppsala, Sweden). Surface coating and monitoring of real‐time binding kinetics and interaction analysis were performed essentially as described ([@b42]). In brief, the chip surface was activated with the amine coupling method and coated with GFP--CBD500 molecules in both flow cells (70 µl of 0.5 mg ml^−1^ protein in 10 mM sodium acetate buffer, pH 5, at a flow rate of 5 µl min^−1^). Heat‐inactivated WSLC 1042 cells in HBS buffer (10 mM Hepes, 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween 20, pH 7.8) were then bound to the immobilized CBDs in flow cell Fc2 (3.0 × 10^10^ cells per ml; 15 µl at a flow rate of 3 µl min^−1^). Finally, interactions between the immobilized cells and three different concentrations of both GFP_CBD500 (50 nM, 100 nM, 200 nM) and GFP_CBD500‐500 (12.5 nM, 25 nM, 50 nM) in HBS buffer were measured (30 µl at 10 µl min^−1^). Fc1 served as reference cell. The association phase was measured for 3 min, the dissociation phase for 12 min. All steps were carried out at 25°C. Evaluation of kinetic data was performed with the BIAevaluation software, version 4.1 (BIAcore), employing a '1:1 binding with mass transfer' model.
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**Table S1.** Primers for PCR amplification and sequencing used in this study.

**Table S2.** Plasmids used in this study.
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